🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI

GINECO-OV244b

Phase 2 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI for Platinum sensitive recurrent ovarian cancer is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Platinum sensitive recurrent ovarian cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials